Literature DB >> 12163391

Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Mark A Watson1, David H Gutmann, Kelly Peterson, Michael R Chicoine, Bette K Kleinschmidt-DeMasters, Henry G Brown, Arie Perry.   

Abstract

Meningiomas are common central nervous system neoplasms that exhibit remarkably diverse histopathology and biological behavior. Compared to astrocytomas, the most common central nervous system tumor, little is known about the molecular pathways critical for meningioma tumor formation and malignant progression. As an initial step toward characterizing the genetic basis of meningioma pathogenesis, we assessed cancer-related gene expression profiles of nonneoplastic leptomeningeal specimens and human meningiomas of varying World Health Organization (WHO) grade using high-density oligonucleotide microarrays. Although expression profile differences between nonneoplastic and meningioma specimens were readily discernible, the expression profile of a subset of genes could also distinguish WHO grade I from WHO grades II and III tumors. Altered expression levels of several genes identified in this study have been previously noted in meningiomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2). However, we also identified a number of novel genes whose expression was associated with WHO grade and was confirmed by reverse transcriptase-polymerase chain reaction in a larger, independent set of meningeal tumors (n = 47). This report represents the first gene expression profiling studies of meningiomas and identifies some initial candidate genes that may provide further insights into the genetic basis for meningioma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163391      PMCID: PMC1850745          DOI: 10.1016/S0002-9440(10)64222-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  A high-density probe array sample preparation method using 10- to 100-fold fewer cells.

Authors:  M Mahadevappa; J A Warrington
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

2.  Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.

Authors:  I E McCutcheon; A Flyvbjerg; H Hill; J Li; W F Bennett; J A Scarlett; K E Friend
Journal:  J Neurosurg       Date:  2001-03       Impact factor: 5.115

3.  The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.

Authors:  G A Mashour; N Ratner; G A Khan; H L Wang; R L Martuza; A Kurtz
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

Review 4.  Occurrence, regulation, and significance of progesterone receptors in human meningioma.

Authors:  M A Blankenstein; F M Verheijen; J M Jacobs; T H Donker; M W van Duijnhoven; J H Thijssen
Journal:  Steroids       Date:  2000 Oct-Nov       Impact factor: 2.668

5.  Gene-expression profiles in hereditary breast cancer.

Authors:  I Hedenfalk; D Duggan; Y Chen; M Radmacher; M Bittner; R Simon; P Meltzer; B Gusterson; M Esteller; O P Kallioniemi; B Wilfond; A Borg; J Trent; M Raffeld; Z Yakhini; A Ben-Dor; E Dougherty; J Kononen; L Bubendorf; W Fehrle; S Pittaluga; S Gruvberger; N Loman; O Johannsson; H Olsson; G Sauter
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

6.  PS6K amplification characterizes a small subset of anaplastic meningiomas.

Authors:  D X Cai; C D James; B W Scheithauer; F J Couch; A Perry
Journal:  Am J Clin Pathol       Date:  2001-02       Impact factor: 2.493

7.  NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas.

Authors:  P E Leone; M J Bello; J M de Campos; J Vaquero; J L Sarasa; A Pestaña; J A Rey
Journal:  Oncogene       Date:  1999-04-01       Impact factor: 9.867

8.  Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases.

Authors:  A Perry; D X Cai; B W Scheithauer; P E Swanson; C M Lohse; I F Newsham; A Weaver; D H Gutmann
Journal:  J Neuropathol Exp Neurol       Date:  2000-10       Impact factor: 3.685

9.  Regulation of growth and tumorigenicity of breast cancer cells by the low molecular weight GTPase Rad and nm23.

Authors:  Y H Tseng; D Vicent; J Zhu; Y Niu; A Adeyinka; J S Moyers; P H Watson; C R Kahn
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

10.  Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas.

Authors:  M A Watson; A Perry; V Budhraja; V Budhjara; C Hicks; W D Shannon; K M Rich
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

View more
  31 in total

1.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

Review 2.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

3.  IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1.

Authors:  Wen-jing Ruan; Jie Lin; En-ping Xu; Fang-ying Xu; Yu Ma; Hong Deng; Qiong Huang; Bing-jian Lv; Hu Hu; Jing Cui; Mei-juan Di; Jian-kang Dong; Mao-de Lai
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

4.  Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

Authors:  Elisa Pérez-Magán; Angel Rodríguez de Lope; Teresa Ribalta; Yolanda Ruano; Yolanda Campos-Martín; Gerardo Pérez-Bautista; Juan Fernando García; Ainoha García-Claver; Concepción Fiaño; José-Luis Hernández-Moneo; Manuela Mollejo; Bárbara Meléndez
Journal:  Neuro Oncol       Date:  2010-08-04       Impact factor: 12.300

5.  Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma.

Authors:  Prakash Rath; Douglas C Miller; N Scott Litofsky; Douglas C Anthony; Qi Feng; Craig Franklin; Lirong Pei; Alan Free; Jimei Liu; Mingqiang Ren; Mark D Kirk; Huidong Shi
Journal:  Exp Mol Pathol       Date:  2010-12-17       Impact factor: 3.362

6.  IGFBP-rP1, a potential molecule associated with colon cancer differentiation.

Authors:  Wenjing Ruan; Shuzhen Zhu; Haibing Wang; Fangying Xu; Hong Deng; Yu Ma; Maode Lai
Journal:  Mol Cancer       Date:  2010-10-26       Impact factor: 27.401

7.  In-vivo transfection of pcDNA3.1-IGFBP7 inhibits melanoma growth in mice through apoptosis induction and VEGF downexpression.

Authors:  Rong-Yi Chen; Hong-Xiang Chen; Jia-Xi Lin; Wei-Bing She; Ping Jiang; Li Xu; Ya-Ting Tu
Journal:  J Exp Clin Cancer Res       Date:  2010-02-16

8.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

9.  Specific genes expressed in association with progesterone receptors in meningioma.

Authors:  Elizabeth B Claus; Peter J Park; Rona Carroll; Jennifer Chan; Peter M Black
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

10.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.